Latest Rituximab Stories

SEATTLE, April 4, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that the April 2011 edition of the peer reviewed journal, Leukemia & Lymphoma (April 2011; 52(4): 620-628) published results of a phase I/II clinical trial evaluating the effect of cyclophosphamide, pixantrone, vincristine, and prednisone ("CPOP") in treating patients with aggressive non-Hodgkin's lymphoma ("NHL") who relapsed following initial therapy with cyclophosphamide,...

- Glenmark's first novel molecule for an oncology indication - GBR 401 is a monoclonal antibody targeting CD19. The antibody is implicated in treatment of B cell malignancies and inflammatory disorders mediated by B lymphocytes - CD19 is expressed earlier and more broadly in B-cell development than CD20 and represents a promising treatment approach - GBR401 has been developed using an advanced technology platform that greatly enhances the efficacy...

SEATTLE, March 21, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL"). The clinical trial is now open to patient enrollment. The trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed...

SEATTLE, March 10, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced the final clinical trial design of a randomized pivotal trial of pixantrone for the treatment of diffuse large B-cell lymphoma ("DLBCL") following discussions with the U.S. Food and Drug Administration's (the "FDA") Division of Hematologic Products (the "DHP") . The new clinical trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus...

Combination therapy for rheumatoid arthritis has consistent safety profileA recent trial of rituximab in combination with a tumor necrosis factor (TNF) inhibitor and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) found the safety profile to be consistent with other RA trials with TNF inhibitors. While the trial reported no new safety risks, clear evidence of an efficacy advantage in RA patients receiving the combination therapy was not observed in this study sample....

New research shows that a less-toxic combination of a targeted immune-based drug and a chemotherapy drug can produce long-term remissions in some chronic lymphocytic leukemia patients. And it does so without increasing the risk of later therapy-related myelodysplastic syndrome and acute myeloid leukemia, which can often occur with a three-drug combination used to treat these patients.The multi-institutional study, led by researchers at the Ohio State University Comprehensive Cancer Center...

BARCELONA, Spain, February 21, 2011 /PRNewswire/ -- ADVANCELL (http://www.advancell.net/), an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia (http://www.cancer.gov/) (CLL) patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of...

SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the first patient received subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze((TM) technology (rHuPH20, recombinant human hyaluronidase). This represents the second Roche cancer medicine, in addition to Herceptin® SC (trastuzumab), to enter a Phase 3 registration study as part of the...

In rheumatoid arthritis patients unresponsive to biologic agentsIn a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied. In contrast to the prior study,...

EXTON, Pa., Dec. 21, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the publication of a new syndicated report focused on the management and treatment of systemic lupus erythematosus (SLE) in the U.S. ChartTrends®: Systemic Lupus Erythematosus is an annual publication based on patient and laboratory data collected from 1,079 lupus patient charts as submitted by 201 rheumatologists. The report provides insight into the factors that drive decisions to treat,...